

DI-077

Toscano Guzmán MD⁽¹⁾, Sierra Torres MI⁽¹⁾, Flores Moreno S⁽¹⁾, Avila Carpio AD⁽²⁾,
Romero Gómez A⁽²⁾, Bautista Paloma FJ⁽¹⁾.

(1)U.G.C. de Farmacia. (2) U.G.C. de Aparato Digestivo. Hospital Virgen del Rocío y Virgen Macarena. Sevilla. (Spain)

INTRODUCTION

Infliximab is one of the most widely used alternatives in ulcerative colitis (UC).
The recent appearance of a biosimilar makes necessary to assess its use

PURPOSE

To assess the effectiveness and safety of biosimilar infliximab in patients with UC.

MATERIAL AND METHODS

Retrospective observational study in a tertiary hospital.

UC Patients

TREAT

Remicade®

SWITCH

Remsima®

Mar-Jun 2015

The **effectiveness** and **safety** were assessed **3 months** after the switch.

Effectiveness (Before and three months after the switch):

- True-Love-Witts scale
- Protein-C reactive(CRP) levels.

Safety: All adverse events.

Variables

- Age.
- Sex.
- Concomitant therapy.
- Disease classification: Montreal scale (severity and extention).
- Effectiveness.
- Adverse events.

RESULTS

25 patients



52% women



X= 45 years (21-71)

Baseline moment:

- 23 patients had stabilized disease
- 2 had minor outbreaks

Treated concomitantly:

- 20% corticosteroids
- 36% azathioprine/mercaptopurine

Montreal scale :

- | | |
|-------------------------|------------------------|
| <u>Extension level:</u> | <u>Severity level:</u> |
| • 72% E3 | • 8% S0 |
| • 28% E2 | • 32% S1 |
| • 0% E1 | • 48% S2 |
| | • 12% S3 |

The effectiveness could be assessed in 12 patients

- ✓ 1 patient had a minor outbreak at the beginning.
- ✓ 8 maintained the same Tru-Love-Witts score
- ✓ 4 decreased it.
- No clinical change happened after the use of the biosimilar.
- No clinically relevant increased in CRP.

No adverse events were detected after the switch

CONCLUSIONS

Despite being a preliminary assessment with just a few patients, initial data show that the switch to an infliximab biosimilar does not represent a decrease in effectiveness and / or safety in patient with UC.

Long term assessment of these patients is guaranteed to confirm these results.